Janssen applies for Invega Sustenna label expansion

|By:, SA News Editor

J&J (JNJ +0.6%) unit Janssen Pharmaceuticals submits an sNDA for a label expansion for its injectable schizophrenia drug Invega Sustenna (paliperidone palmitate) for the treatment of schizoaffective disorder as a monotherapy or adjunctive therapy.

If cleared, it will be the only long-acting injectable drug approved for the condition.

The product has been available since 2009 as a treatment for schizophrenia.